Skip to content

Broad spectrum antiviral, pegylated interferon lambda, found to be highly effective for early treatment of COVID-19 across dominant variants

By Gold Cross - February 10, 2023

This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

Pharmacist Only
,

Medical professionals fear cases of B6 toxicity are under-reported

Gold Cross | January 28, 2025
,

What’s the difference between a food allergy and an intolerance?

Gold Cross | January 28, 2025
, ,

Oyster ‘blood’ holds promise for combating drug-resistant superbugs: new research

Gold Cross | January 21, 2025
,

Stoking “good” antibodies key to reducing serious bee venom allergic reactions

Gold Cross | January 21, 2025
BD Rowa automation gives you back 6 hours in your day

Latest Posts

New link revealed between hypertension and the gut
Gold Cross | January 30, 2025
Pharmacist Only
Final Call: APP2025 Early Bird pricing ends tomorrow!
Gold Cross | January 30, 2025
Pharmacist Only
Medical professionals fear cases of B6 toxicity are under-reported
Gold Cross | January 28, 2025

Featured Posts

Nurturing brain health for business owners
Gold Cross | January 28, 2025
How genuine conversations impact high performing teams
Gold Cross | December 10, 2024
Protecting your pharmacy: online reviews and defamation explained
Gold Cross | December 3, 2024

Tags

Scroll To Top